Back to top
more

Infinity Pharmaceuticals, Inc. (INFI)

(Delayed Data from NSDQ)

$1.71 USD

1.71
99,328

+0.06 (3.64%)

Updated May 3, 2019 04:00 PM ET

After-Market: $1.72 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zoetis (ZTS) Beats Earnings, Revenue Estimates in Q1

by Zacks Equity Research

Zoetis Inc. (ZTS) first-quarter 2017 earnings of 53 cents per share increased 10% year over year and surpassed the Zacks Consensus Estimate of 48 cents.

    Novo Nordisk (NVO) Beats on Q1 Earnings, Revenues Down Y/Y

    by Zacks Equity Research

    Novo Nordisk A/S (NVO) reported first-quarter 2017 earnings of 58 cents per American Depositary Receipt (ADR) beating the Zacks Consensus Estimate of 53 cents by 9.4%.

      VIVUS (VVUS) Loss Narrower than Expected, Revenues Up Y/Y

      by Zacks Equity Research

      VIVUS Inc. (VVUS) reported a loss of 1 cent per share in the first quarter of 2017, which was narrower than a loss of 12 cents in the year-ago period as well as the Zacks Consensus Estimate of a loss of 13 cents

        Aerie (AERI) Posts Wider-Than-Expected Q1 Loss, Expenses Up

        by Zacks Equity Research

        Aerie Pharmaceuticals, Inc. (AERI) posted first-quarter 2017 loss of 76 cents per share (including stock-based compensation), wider than the Zacks Consensus Estimate of a loss of 74 cents.

          Shire (SHPG) Beats on Q1 Earnings & Sales, Reiterates View

          by Zacks Equity Research

          Shire plc (SHPG) reported first-quarter 2017 earnings of $3.63 per American Depositary Share (ADS), beating the Zacks Consensus Estimate of $3.22 and up 13.8% from the year-ago quarter figure of $3.19.

            Gilead (GILD) Beats on Q1 Earnings, Revenues Miss Estimates

            by Zacks Equity Research

            Gilead Sciences, Inc.'s (GILD) first-quarter 2017 earnings (including the impact of stock-based compensation expenses) of $2.20 per share beat the Zacks Consensus Estimate of $2.18.

              Alkermes (ALKS) Q1 Loss Wider than Expected, Sales Miss

              by Zacks Equity Research

              Alkermes plc (ALKS) reported loss of 31 cents per share (including the impact of share-based compensation expense) in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 24 cents.

                Glaxo (GSK) Reports In-Line Q1 Earnings, Reiterates View

                by Zacks Equity Research

                GlaxoSmithKline plc's (GSK) first quarter results came roughly in line with expectations. Glaxo reported first-quarter 2017 core earnings of 62 cents per American Depositary Share (ADS), in line with the Zacks Consensus Estimate.

                  Alexion (ALXN) Tops Q1 Earnings, Revenues; Ups '17 View

                  by Zacks Equity Research

                  Alexion Pharmaceuticals, Inc.'s (ALXN) first-quarter 2017 earnings (including stock-based compensation expense) of $1.20 per share compared with the year ago earnings of 76 cents. The reported figure surpassed the Zacks Consensus Estimate of $1.05.

                    Celgene (CELG) Tops on Q1 Earnings, Sales Miss, Raises View

                    by Zacks Equity Research

                    Celgene's (CELG) first-quarter results were mixed, with the company beating on earnings but missing on sales.

                      AbbVie (ABBV) Presents Positive Data on HCV Combination Drug

                      by Zacks Equity Research

                      AbbVie Inc. (ABBV) announced that data from two phase III studies, EXPEDITION-1 and ENDURANCE-3, evaluating its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P) for all genotypes of Hepatitis C virus (HCV)

                        Nivalis' (NVLS) Shares Down After Merger Deal with Alpine

                        by Zacks Equity Research

                        The announcement of Nivalis Therapeutics, Inc.'s (NVLS) merger agreement with a privately-held biotechnology company, Alpine Immune Sciences, Inc. failed to excite investors.

                          Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III

                          by Zacks Equity Research

                          Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Hakko Kirin Co., Ltd announced positive data from a phase III study evaluating its pipeline candidate burosumab (KRN23) in adults with X-linked hypophosphatemia (XLH).

                            Why Is Infinity (INFI) Down 37.4% Since the Last Earnings Report?

                            by Zacks Equity Research

                            Infinity (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                              AMAG Files for FDA Approval of Subcutaneous Form of Makena

                              by Zacks Equity Research

                              AMAG Pharmaceuticals, Inc. (AMAG) announced the submission of a supplemental New Drug Application (sNDA) to the FDA for the subcutaneous auto-injector form of its marketed drug Makena in the U.S.

                                Infinity Pharmaceuticals (INFI) Looks Good: Stock Jumps 19%

                                by Zacks Equity Research

                                Infinity Pharmaceuticals, Inc. (INFI) shares rose over 19% in the last trading session.

                                  Bio-Path Holdings (BPTH) Looks Good: Stock Moves 13% Higher

                                  by Zacks Equity Research

                                  Bio-Path Holdings, Inc. (BPTH) shares rose over 13% in the last trading session.

                                    Should You Retain Universal Health (UHS) Stock in Portfolio?

                                    by Zacks Equity Research

                                    Universal Health Services, Inc. (UHS) stock has gained 9% in last three months, outperforming the Zacks Hospitals industry's increase of 7.6%.

                                      Ultragenyx's (RARE) XLH Drug Positive in Phase II Study

                                      by Zacks Equity Research

                                      Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Kirin International plc recently announced positive 64-week data from a pediatric phase II study, evaluating its investigational candidate burosumab (KRN23).

                                        Here's Why You Should Dump Tenet Healthcare (THC) Stock Now

                                        by Zacks Equity Research

                                        Texas-based health care services company Tenet Healthcare Corp. (THC) seems to have fallen out of favor with investors.

                                          Infinity Pharmaceuticals Focuses on Lead Candidate IPI-549

                                          by Zacks Equity Research

                                          We issued an updated report on Infinity Pharmaceuticals, Inc. (INFI) on Apr 7.

                                            Cardiome Pharma (CRME) Jumps: Stock Adds 6.6% in Session

                                            by Zacks Equity Research

                                            Cardiome Pharma Corp. (CRME) shares rose over 6% in the last trading session.

                                              Tirthankar Chakraborty headshot

                                              New Strong Buy Stocks for April 10th

                                              by Tirthankar Chakraborty

                                              Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday

                                                Should You Retain Acadia Healthcare Stock in Your Portfolio?

                                                by Zacks Equity Research

                                                The Acadia Healthcare Company, Inc. (ACHC) stock gained momentum in the first quarter of 2017

                                                  Increased Earnings Estimates Seen for Infinity (INFI): Can It Move Higher?

                                                  by Zacks Equity Research

                                                  Infinity (INFI) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision.